ZA201301747B - Oxadiazole inhibitors of leukotriene production - Google Patents

Oxadiazole inhibitors of leukotriene production

Info

Publication number
ZA201301747B
ZA201301747B ZA2013/01747A ZA201301747A ZA201301747B ZA 201301747 B ZA201301747 B ZA 201301747B ZA 2013/01747 A ZA2013/01747 A ZA 2013/01747A ZA 201301747 A ZA201301747 A ZA 201301747A ZA 201301747 B ZA201301747 B ZA 201301747B
Authority
ZA
South Africa
Prior art keywords
leukotriene production
oxadiazole
inhibitors
oxadiazole inhibitors
leukotriene
Prior art date
Application number
ZA2013/01747A
Other languages
English (en)
Inventor
Alessandra Bartolozzi
Zhidong Chen
Jonathon Alan Dines
Weimin Liu
Tina Marie Morwick
Doris Riether
Lifen Wu
Todd Bosanac
Lombaert Stephane De
John D Huber
Pui Leng Loke
Alan Olague
Heather Tye
Renee M Zindell
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44720163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201301747(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of ZA201301747B publication Critical patent/ZA201301747B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA2013/01747A 2010-09-23 2013-03-07 Oxadiazole inhibitors of leukotriene production ZA201301747B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38573310P 2010-09-23 2010-09-23
US201161533349P 2011-09-12 2011-09-12
PCT/US2011/052254 WO2012040139A1 (en) 2010-09-23 2011-09-20 Oxadiazole inhibitors of leukotriene production

Publications (1)

Publication Number Publication Date
ZA201301747B true ZA201301747B (en) 2014-08-27

Family

ID=44720163

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2013/01747A ZA201301747B (en) 2010-09-23 2013-03-07 Oxadiazole inhibitors of leukotriene production

Country Status (19)

Country Link
US (1) US8575201B2 (enExample)
EP (1) EP2619197B1 (enExample)
JP (1) JP5713511B2 (enExample)
KR (1) KR20130109122A (enExample)
CN (1) CN103261193A (enExample)
AU (1) AU2011305667A1 (enExample)
BR (1) BR112013008638A2 (enExample)
CA (1) CA2812449A1 (enExample)
CL (1) CL2013000788A1 (enExample)
CO (1) CO6710902A2 (enExample)
EA (1) EA201300389A1 (enExample)
EC (1) ECSP13012548A (enExample)
IN (1) IN2013DN02555A (enExample)
MX (1) MX2013003202A (enExample)
PE (1) PE20131398A1 (enExample)
PH (1) PH12013500545A1 (enExample)
SG (1) SG188604A1 (enExample)
WO (1) WO2012040139A1 (enExample)
ZA (1) ZA201301747B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3150164B2 (ja) 1991-05-01 2001-03-26 電気化学工業株式会社 セメント混和材及びセメント組成物
WO2012027322A1 (en) * 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
EP2619196B1 (en) * 2010-09-23 2015-09-16 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production
EA201300389A1 (ru) 2010-09-23 2013-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Оксадиазольные ингибиторы продуцирования лейкотриена
AR089853A1 (es) 2012-02-01 2014-09-24 Boehringer Ingelheim Int Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
EP3495359A1 (en) * 2013-02-04 2019-06-12 Janssen Pharmaceutica NV Flap modulators
EP2875736B1 (en) 2013-11-26 2016-07-27 Citrage N-Carbamoylputrescine to enhance muscle protein synthesis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2260031T3 (es) 1999-08-06 2006-11-01 Janssen Pharmaceutica N.V. Derivados de 6-azauracilo que inhiben la interleucina-5.
JP2007502300A (ja) * 2003-08-13 2007-02-08 カイロン　コーポレイション Ｇｓｋ−３インヒビターおよびその使用
US7319108B2 (en) 2004-01-25 2008-01-15 Sanofi-Aventis Deutschland Gmbh Aryl-substituted heterocycles, process for their preparation and their use as medicaments
AU2005295646B2 (en) 2004-10-18 2008-11-20 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes as flap inhibitors
US7977359B2 (en) * 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) * 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
AU2007238878A1 (en) 2006-04-11 2007-10-25 Merck Sharp & Dohme Corp. Diaryl substituted alkanes
CA2787343C (en) 2006-06-26 2016-08-02 Amgen Inc. Compositions comprising modified lcat and uses thereof
ATE543810T1 (de) 2006-09-01 2012-02-15 Merck Sharp & Dohme Hemmer des 5-lipoxygenase aktivierenden proteins (flap)
AU2008241313A1 (en) 2007-04-20 2008-10-30 Merck Frosst Canada Ltd. Novel heteroaromatic compounds as inhibitors of stearoyl-coenzyme a delta-9 desaturase
CA2707360A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Diphenyl substituted alkanes
WO2009048547A1 (en) 2007-10-10 2009-04-16 Merck & Co., Inc. Diphenyl substituted cycloalkanes
DE102008037790A1 (de) * 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
CA2741666C (en) * 2008-10-31 2017-04-11 Merck Sharp & Dohme Corp. P2x3, receptor antagonists for treatment of pain
CA2749893A1 (en) 2009-02-04 2010-08-12 Pfizer Inc. 4-amino-7,8-dihydropyrido[4,3-d]pyrimidin-5(6h)-one derivatives
EP2568809A4 (en) 2010-05-12 2013-11-06 Univ Vanderbilt HETEROCYCLIC ALLOSTERE SULFON MGLUR4 POTENTIATORS, COMPOSITIONS AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTIONS
PH12013500301A1 (en) * 2010-08-16 2013-03-25 Boehringer Ingelheim Int Oxadiazole inhibitors of leukotriene production
WO2012027322A1 (en) * 2010-08-26 2012-03-01 Boehringer Ingelheim International Gmbh Oxadiazole inhibitors of leukotriene production
EA201300389A1 (ru) 2010-09-23 2013-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Оксадиазольные ингибиторы продуцирования лейкотриена
EP2619196B1 (en) * 2010-09-23 2015-09-16 Boehringer Ingelheim International GmbH Oxadiazole inhibitors of leukotriene production

Also Published As

Publication number Publication date
WO2012040139A1 (en) 2012-03-29
ECSP13012548A (es) 2013-06-28
KR20130109122A (ko) 2013-10-07
EA201300389A1 (ru) 2013-09-30
CA2812449A1 (en) 2012-03-29
EP2619197B1 (en) 2015-08-05
US8575201B2 (en) 2013-11-05
AU2011305667A1 (en) 2013-03-21
CO6710902A2 (es) 2013-07-15
MX2013003202A (es) 2013-04-24
JP2013537909A (ja) 2013-10-07
IN2013DN02555A (enExample) 2015-08-07
EP2619197A1 (en) 2013-07-31
JP5713511B2 (ja) 2015-05-07
PH12013500545A1 (en) 2013-05-06
CN103261193A (zh) 2013-08-21
BR112013008638A2 (pt) 2016-06-21
SG188604A1 (en) 2013-04-30
PE20131398A1 (es) 2013-12-19
CL2013000788A1 (es) 2013-06-28
US20120295896A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
ZA201300238B (en) Oxadiazole inhibitors of leukotriene production
AP3339A (en) Benzodioxane inhibitors of leukotriene production
IL237581B (en) Derivatives of 6-oxo-pyrazinopyrrolopyrimidines
EP2576552A4 (en) BENZOQUINOLONE INHIBITORS OF VMAT2
ZA201206456B (en) Uses of dgati inhibitors
ZA201309561B (en) Novel inhibitor compounds of phosphodiestarase type 10a
EP2678018A4 (en) COMBINATION OF CHINESE HEMMER AND USES THEREOF
ZA201209407B (en) Modification of xylan
IL218018A0 (en) Novel n-substituted-pyrrolidines as inhibitors of mdm2-p-53 interactions
GB201003274D0 (en) Methods of connecting
ZA201300004B (en) Cyrstalline form of benzylbenzene sglt2 inhibitor
ZA201403995B (en) Stereoselective total synthesis of noribogaine
GB201002606D0 (en) Production of fuels
EP2553108A4 (en) PRODUCTION OF MONOTERPENES
GB201215633D0 (en) Use of autotransformer-like atennas for downhole applications
SG10201601023UA (en) Inhibitors of nedd8-activating enzyme
ZA201301752B (en) Improved production of prtein solutions from soy
GB201120696D0 (en) Production of mono-cystalline silicon
GB201004096D0 (en) Production of polyhydroalkanoates
BR112013008638A2 (pt) inibidores de oxadiazol de produção de leucotrieno
GB201008573D0 (en) Biocatalytic production of cellobiosides
PL2513060T3 (pl) Krystaliczna postać α karbabenzopirydu
PT2603319E (pt) Processo para a preparação de uretanos
AP2013006762A0 (en) Oxadiazole inhibitors of leukotriene production
ZA201209648B (en) Crystalline forms of kinase inhibitors